Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$9.9MCash on Hand
8.2mo Cash Runway
Follow CLNN by emailGet an email when CLNN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CLNN, unsubscribe in one click. Privacy
📣 What CLNN Says Is Next
second quarter of 2027 · “Clene plans to randomize the first participants for the Phase 3 RESTORE-ALS trial in the second quarter of 2027.”
Company press release, Nov 4, 2026 · SEC filing
second quarter of 2027 · CNM-Au8: “Plans to initiate the Phase 3 RESTORE-ALS confirmatory trial of CNM-Au8 in ALS in the second quarter of 2027 SALT LAKE CITY, November 4, 2026 -- Clene Inc. (Nasdaq: CLNN), a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced its third quarter 2026 financial results and provided updates on its CNM-Au8 programs.”
Company press release, Nov 4, 2026 · SEC filing
first quarter of 2027 · “The Company is conducting the Phase 3 confirmatory study for CNM-Au8, which it intends to commence in the first quarter of 2027.”
Company press release, May 4, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 4, 2026 ·
Earnings Reported Q3 2026 net income of $3.9 million, or $0.05 per diluted share, versus a net loss of $8.8 million a year earlier, driven by a $10.3 million swing in other income from warrant and derivative fair value changes. Cash was $9.9 million, with runway through mid-first quarter 2027. Form 8-K · SEC filing · Press release
Nov 4, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 20, 2026 ·
Deal Clene Nanomedicine entered a subaward amendment with NYU on October 15, 2026, for the fourth year of a $45.1 million NIH grant, providing up to $7.2 million for September 1, 2026 to August 31, 2027. The grant supports an Expanded Access Program for CNM-Au8 in ALS. Form 8-K · SEC filing
Oct 19, 2026 ·
Regulatory Announced the submission of a New Drug Application to the FDA seeking accelerated approval of CNM-Au8 for the treatment of ALS, based on neurofilament light chain biomarker data and clinical outcomes. The company is preparing for the confirmatory Phase 3 RESTORE-ALS study. Form 8-K · SEC filing · Press release
Sep 16, 2026 ·
Financing Clene is offering 1,219,513 shares of common stock at $3.28 per share directly to certain existing stockholders, including directors and officers, for proceeds of about $4.0 million before expenses. Directors and officers will buy about $2.1 million of the shares. Form 424B5 · SEC filing
Sep 16, 2026 ·
Financing Clene agreed to sell 1,219,513 shares at $3.28 per share in a registered direct offering to existing stockholders, including directors and officers, for gross proceeds of about $4.0 million. Closing is expected September 17, 2026, with proceeds for general corporate purposes including the CNM-Au8 regulatory effort. Form 8-K · SEC filing · Press release
Aug 14, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Aug 14, 2026 ·
Earnings Clene reported Q2 2026 net loss of $13.4 million, or $1.08 per share, versus $7.4 million, or $0.78 per share, a year earlier. Cash was $9.7 million at June 30, 2026, with runway through late fourth quarter 2026. The company expects to submit an NDA for CNM-Au8 in ALS under accelerated approval in early Q4 2026. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jun 2026 · Phase 2 · Active Trial · An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease… Registry date passed, readout not confirmed
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
CLNN holds $9.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.6M/quarter from operations,
an estimated runway of 8.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:84 · High
Cash runway 8 months +30
ATM program on file since Oct 2025 +15
Shelf registration (S-3, Mar 2025) +10
Going-concern doubt in the latest 10-Q +15These conditions raise substantial doubt about the Company’s ability to continue as a going concern.10-Q, Nov 2026
Share count 14,400,175 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CLNN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.